What does evidence say about PRP for GSM?
What does evidence say about PRP for GSM? Platelet-rich plasma (PRP) is being explored as an adjunct for genitourinary syndrome of menopause, but high-quality data are limited. Small, short-term studies suggest possible improvements in dryness and dyspareunia, yet results are heterogeneous and durability is uncertain compared with guideline-backed options like moisturisers, lubricants and local oestrogen. If considered, PRP should follow a stepwise plan with clear goals, aftercare and review. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
What does evidence say about PRP for GSM? Platelet-rich plasma (PRP) is prepared from your own blood and contains platelets and growth-factor-rich plasma. It is injected or applied to target tissues with the aim of supporting mucosal hydration, surface slip and micro-healing. In the context of genitourinary syndrome of menopause (GSM)—also called vaginal dryness/atrophy—PRP is positioned as an adjunct, not a replacement for foundations (scheduled vaginal moisturiser + compatible lubricant) or guideline-supported local vaginal oestrogen (or DHEA). Early clinical reports suggest some women notice softer tissue feel, less urine sting on contact, and fewer “paper-cut” micro-tears at the entrance (vestibule/posterior fourchette) after a short series. However, published studies are generally small, vary in how PRP is prepared and placed, and often follow participants for only a few months—so it’s hard to judge durability or to compare PRP directly with local oestrogen.
What a realistic pathway looks like. We start with a foundation-first plan: a fragrance-free, minimal-ingredient vaginal moisturiser 2–4 nights weekly and a generous personal lubricant for higher-friction moments (water-based for versatility/condoms; silicone-based for the longest glide on a tender vestibule; avoid oil-based with latex). If acceptable, add local vaginal oestrogen (cream, tablet/pessary or ring) or vaginal DHEA. Placement matters: if stinging is entrance-focused, add a fingertip of cream at the vestibule and the posterior fourchette, not just internally. Only when these steps are optimised and still leave gaps do we discuss PRP as a targeted adjunct.
What to expect if you try PRP. Typical plans use 2–3 sessions, spaced 4–8 weeks apart, directed to the symptomatic sites (often the vestibule). You may have temporary tenderness, pinpoint bruising or light spotting. Most people pause high-friction activities and intimacy until tenderness settles (commonly 3–5 days). You continue foundations so any benefit is easier to feel and maintain. Because the evidence base is evolving, we build in reviews (6–12 weeks after a series) to decide whether maintenance is worthwhile or whether optimised foundations suffice.
Safety and suitability. As an autologous product, PRP avoids foreign fillers, but it still involves needles and clinic processing. People on anticoagulants may bruise more and need an individual plan; active infection (BV/thrush/UTI), malodorous discharge, fever, or new post-menopausal bleeding are reasons to defer and prioritise diagnosis. Severe fish allergy is not relevant to PRP (it is to some polynucleotides). Any unexpected or serious effects should be reported through the UK Yellow Card system. For how these options fit step-by-step, see how treatment steps are sequenced and the practical outcomes we monitor under treatment benefits.
How PRP compares with local therapies. Guideline-backed local oestrogen (or DHEA) improves epithelial maturity and pH over weeks and has stronger evidence for dryness, soreness and dyspareunia than any regenerative adjunct to date. PRP may be discussed where local hormones are unsuitable or declined, or as an add-on when entrance-focused micro-tears persist despite good placement and friction control. Expectations should be conservative and centred on comfort and function in daily life.
Clinical Context
Who might consider PRP? People whose main limiter is vestibular sting and micro-tears with penetration or movement, despite excellent foundations and well-placed local therapy; those who cannot use local hormones may also explore PRP after optimising non-hormonal care.
Who should avoid or delay PRP now? Anyone with active BV/thrush/UTI, malodorous discharge, fever, new post-menopausal bleeding, or recent pelvic/perineal surgery without clearance. If deep pelvic pain dominates, pelvic floor physiotherapy and graded dilators are higher-yield—PRP does not relax muscles.
Alternatives & next steps. Many achieve comfort with a scheduled vaginal moisturiser plus a generous, compatible lubricant and correct vestibule placement of creams. If hormones are acceptable, local oestrogen/DHEA usually improves dryness and soreness within 2–6 weeks. Keep ingredient lists short and unscented; rinse chlorine after swimming; choose breathable fabrics.
Educational only. Results vary. Not a cure.
Evidence-Based Approaches
NHS overview (patient-facing): Practical guidance on symptoms, moisturisers, lubricants and when to seek help for vaginal dryness.
NICE guideline framing: The NICE Menopause Guideline (NG23) supports first-line use of vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when quality of life is affected.
Evidence landscape for PRP: Public abstracts indexed on PubMed report small, heterogeneous studies of PRP for GSM-related symptoms; durability and comparative effectiveness remain uncertain.
Systematic review context: The Cochrane Library provides methods-rigorous reviews; current summaries for device/regenerative options highlight limited, short-term data and the need for robust trials before routine use.
Safety reporting (UK): Suspected adverse events can be reported via the regulator’s MHRA Yellow Card site; this underpins vigilance for all clinic-delivered therapies.